Inflammatory beast cancer represents 2-5% of all malignant breast lesions. Its rapid progression, the rather short medical history of the disease is unique and seems to be very typical. The combined modality treatment of inflammatory breast cancer is a special challange for the medical oncologists. Preoperative chemotherapy is of great importance. After getting fair remission, surgery and radiotherapy should be delivered. With combined modality therapy the 5-year overall survival is about 50%. Knowing more pharmacogenomical details on the disease and delivering new medicaments the effectiveness of the treatment will be further enhanced.
|Translated title of the contribution||Komplex treatment of inflammatory breast cancer|
|Number of pages||5|
|Publication status||Published - dec. 1 2006|
ASJC Scopus subject areas